Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X:
”Pre-emptive rituximab stopped relapses in our iTTP patients.
After 3-5 prior relapses each and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 – 68 months)
This is a big deal for a tough disease. Grateful to my mentor, Dr. Khawandanah and our team. More studies are needed, but hope is here.
Super thankful to all of our mentor – Dr James N George, truly a difference maker in these patients, and in his mentees’ careers.
The fellows at OU Health Stephenson Cancer Center continue to shine; we have the best leadership and the fellowship program director (Dr. Sami Ibrahimi).”
Keep up with Hemostasis Today.
-
Mar 16, 2026, 15:08Mohamed Sikkander Abdul Razak: Warning Signs of Vitamin Deficiencies
-
Mar 16, 2026, 15:05Kate Thomas: Plasma Donations Drive New Era of Life-Saving Medicines in the UK
-
Mar 16, 2026, 14:52Gianluca Franceschini: The Difference in Breast Cancer is Made by the Team
-
Mar 16, 2026, 14:51Heghine Khachatryan: Hematologic Causes of Cryptogenic Stroke
-
Mar 16, 2026, 14:35Simon Senanu: Understanding the Extrinsic Coagulation Pathway
-
Mar 16, 2026, 14:27Mahesan Subramaniam: Why Messy Spaces Impact Women’s Stress Levels More Than Men’s
-
Mar 16, 2026, 14:21Marlies Alvarenga: Balancing the Scales in Women’s Cardiovascular Health
-
Mar 16, 2026, 13:32Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
-
Mar 16, 2026, 13:12Mariia Kumskova։ New Insights Into Platelet Dysfunction in Ehlers-Danlos Syndrome